ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q4 2025 · 103 positions · Total reported value $4.71B · Top-10 concentration 41.3% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q4 2025 13F filing, ORBIMED ADVISORS LLC disclosed 103 equity positions with a combined reported value of $4.71B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 41.3% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2025 were EWTX ($385.09M), LLY ($323.69M), BSX ($230.68M). By sector, the heaviest allocations are Health Care 83.5%, Industrials 3.5%. Versus the prior quarter, allocation shifted toward Industrials (+1.0pp) and away from Health Care (-0.8pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q4 2025 were BMY ($41.80M), ELV ($34.74M), HELP ($31.42M).

Of the 23 positions fully exited versus the prior quarter, the largest were SIBN ($37.96M), SCPH ($34.36M), ITGR ($29.97M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2025)

  • BMY BRISTOL-MYERS SQUIBB CO · $41.80M
  • ELV ELEVANCE HEALTH INC FORMERLY · $34.74M
  • HELP CYBIN INC · $31.42M
  • PRAX PRAXIS PRECISION MEDICINES INC COM NEW · $27.85M
  • BRKR BRUKER CORP · $26.18M
  • ESPR ESPERION THERAPEUTICS INC NE · $22.07M
  • LXEO LEXEO THERAPEUTICS INC · $21.10M
  • VERA VERA THERAPEUTICS INC CL A · $17.90M

Fully Exited (vs previous quarter)

  • SIBN SI BONE INC · prev qtr: $37.96M
  • SCPH SCPHARMACEUTICALS INC · prev qtr: $34.36M
  • ITGR INTEGER HLDGS CORP COM · prev qtr: $29.97M
  • AKRO AKERO THERAPEUTICS INC · prev qtr: $24.98M
  • ABT ABBOTT LABORATORIES · prev qtr: $20.09M
  • AZN ASTRAZENECA PLC · prev qtr: $11.51M · history
  • AMLX AMYLYX PHARMACEUTICALS INC COM · prev qtr: $10.20M
  • VSTM VERASTEM INC COM NEW · prev qtr: $7.84M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 83.5%
Other 13.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 15.52M $385.09M 8.18%
8.18%
Hold
2 301.20K $323.69M 6.88%
6.88%
Hold
3 2.42M $230.68M 4.90%
4.90%
Add
4 2.72M $184.47M 3.92%
3.92%
Hold
5 5.69M $154.58M 3.28%
3.28%
Hold
6 263.40K $149.18M 3.17%
3.17%
Reduce
7 3.56M $146.53M 3.11%
3.11%
Reduce
8 3.94M $124.12M 2.64%
2.64%
Reduce
9 146.00K $122.78M 2.61%
2.61%
Reduce
10 7.96M $122.58M 2.60%
2.60%
Hold
11 288.80K $114.84M 2.44%
2.44%
Reduce
12 325.00K $114.23M 2.43%
2.43%
Reduce
13 8.29M $96.56M 2.05%
2.05%
Hold
14 2.15M $86.99M 1.85%
1.85%
Reduce
15 1.07M $84.77M 1.80%
1.80%
Reduce
16 3.12M $84.07M 1.79%
1.79%
Add
17 365.80K $83.80M 1.78%
1.78%
Reduce
18 15.22M $81.73M 1.74%
1.74%
Hold
19 1.16M $80.80M 1.72%
1.72%
Add
20 299.80K $68.63M 1.46%
1.46%
Add
21 1.52M $62.97M 1.34%
1.34%
Reduce
22 2.43M $61.04M 1.30%
1.30%
Add
23 3.03M $60.91M 1.29%
1.29%
Hold
24 205.00K $56.42M 1.20%
1.20%
Add
25 1.64M $55.64M 1.18%
1.18%
Add
26 7.17M $55.17M 1.17%
1.17%
Hold
27 105.20K $51.26M 1.09%
1.09%
Reduce
28 367.90K $49.61M 1.05%
1.05%
Reduce
29 2.19M $47.54M 1.01%
1.01%
Reduce
30 999.00K $46.50M 0.99%
0.99%
Add
31 253.12K $46.23M 0.98%
0.98%
Reduce
32 2.47M $45.10M 0.96%
0.96%
Add
33 619.53K $44.69M 0.95%
0.95%
Reduce
34 314.24K $44.57M 0.95%
0.95%
Reduce
35 2.20M $43.07M 0.92%
0.92%
Reduce
36 775.00K $41.80M 0.89%
0.89%
New
37 1.65M $41.16M 0.87%
0.87%
Add
38 3.19M $39.95M 0.85%
0.85%
Reduce
39 2.41M $37.15M 0.79%
0.79%
Reduce
40 171.98K $36.67M 0.78%
0.78%
Reduce
41 351.72K $35.72M 0.76%
0.76%
Reduce
42 980.40K $35.58M 0.76%
0.76%
Reduce
43 99.10K $34.74M 0.74%
0.74%
New
44 1.20M $32.64M 0.69%
0.69%
Hold
45 10.91M $31.64M 0.67%
0.67%
Hold
46 3.84M $31.42M 0.67%
0.67%
New
47 3.64M $29.79M 0.63%
0.63%
Hold
48 119.80K $29.54M 0.63%
0.63%
Add
49 94.50K $27.85M 0.59%
0.59%
New
50 1.95M $26.97M 0.57%
0.57%
Add

FAQ

What did ORBIMED ADVISORS LLC buy in 2025-Q4?

In its 2025-Q4 13F filing, ORBIMED ADVISORS LLC reported 103 equity positions worth $4.71B in aggregate; its largest disclosed positions were EWTX ($385.09M), LLY ($323.69M), BSX ($230.68M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.71B of long equity holdings across 103 positions as of 2025-Q4. Top-10 holdings account for 41.3% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →